SMP-114 + methotrexate

SMP-114 + methotrexate is an investigational combination therapy consisting of SMP-114, a candidate disease-modifying anti-rheumatic drug (DMARD), and methotrexate, an established antimetabolite and immunosuppressant used in rheumatoid arthritis and other diseases. The combination was evaluated in phase II clinical trials for the treatment of active rheumatoid arthritis, where SMP-114 was administered at 120 mg or 240 mg doses daily in addition to ongoing methotrexate therapy. Methotrexate acts primarily as a folate antagonist, inhibiting enzymes involved in nucleotide synthesis, resulting in immunosuppressive, anti-inflammatory, and antiproliferative effects[1][3][6][5][9]. The specific molecular target or mechanism of action for SMP-114 has not been disclosed in publicly available sources. The primary aim of the combination is to enhance efficacy in reducing disease activity compared to methotrexate monotherapy[1][3][5][9]. The clinical development was sponsored by Dainippon Sumitomo Pharma Europe and appears to have been discontinued or stopped as per clinical trial records[1][5][9].